Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria.

In the last decades, there was an important paucity of agents for adequately treating infections due to metallo-β-lactamases-producing Gram-negative bacteria (MBL-GNB). Cefiderocol, a novel siderophore cephalosporin showing in vitro activity against MBL-GNB, has been recently marketed, and a combination of aztreonam and ceftazidime/avibactam has shown a possible favorable effect on survival of patients with severe MBL-GNB infections in observational studies. Other agents showing in vitro activity against MBL-GNB are currently in clinical development (e.g., cefepime/taniborbactam, LYS228, cefepime/zidebactam) that could be an important addition to our future armamentarium for severe MBL-GNB infections. Nonetheless, we should not discontinue our efforts to optimize the use of non-β-lactams agents, since they could remain an essential last-resort or alternative option in selected cases.

• Publication year

  2020

• Venue

  Future Microbiology

• Publication date

  2020-11-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fmb-2020-0210PMID 33140656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of β-Lactamase-Producing Pathogens

  2020cited by this paper
• The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria

  2020cited by this paper
• Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.

  2020cited by this paper
• Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019

  2020cited by this paper
• New treatment options for multiresistant gram negatives.

  2020cited by this paper
• Prevalence of the β-lactamase and Antibiotic Resistant Pseudomonas aeruginosa in the Arab Region.

  2020cited by this paper
• Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase–Producing Enterobacterales During a Regional Outbreak

  2020cited by this paper
• Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

  2020cited by this paper
• Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications.

  2020cited by this paper
• Genomic dynamics of species and mobile genetic elements in a prolonged blaIMP-4-associated carbapenemase outbreak in an Australian hospital

  2020cited by this paper
• Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from global surveillance program (SIDERO-WT-2014).

  2020cited by this paper
• Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline

  2020cited by this paper
• Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections

  2020cited by this paper
• Unusually High Prevalence of Cosecretion of Ambler Class A and B Carbapenemases and Nonenzymatic Mechanisms in Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa in Lebanon

  2020cited by this paper
• Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.

  2020cited by this paper
• Use of colistin in adult patients: a cross-sectional study.

  2020cited by this paper
• In Vitro Activity of Aztreonam-Avibactam against Metallo-β-lactamase producing Enterobacteriaceae - a Multi-center study in China.

  2020cited by this paper
• The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms

  2020cited by this paper
• Tolerance to antibiotics affects response

  2020cited by this paper
• Effect of tolerance on the evolution of antibiotic resistance under drug combinations

  2020cited by this paper
• Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales.

  2020cited by this paper
• In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.

  2020cited by this paper
• Critical analysis of antibacterial agents in clinical development

  2020cited by this paper
• β-Lactamases and β-Lactamase Inhibitors in the 21st Century. Journal of Molecular Biology.

  2019cited by this paper
• Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.

  2019cited by this paper
• Treatment of Infections Due to MDR Gram-Negative Bacteria

  2019cited by this paper
• Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program

  2019cited by this paper
• Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens

  2019cited by this paper
• Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial

  2019cited by this paper
• Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria

  2019cited by this paper
• In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae

  2019cited by this paper
• NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings

  2019cited by this paper
• Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

  2019cited by this paper
• Successful control of the first OXA-48 and/or NDM carbapenemase-producing Klebsiella pneumoniae outbreak in Slovenia 2014-2016.

  2019cited by this paper
• In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

  2019cited by this paper
• VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

  2019cited by this paper
• Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

  2019cited by this paper
• Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

  2019cited by this paper
• Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

  2019cited by this paper
• Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance

  2019cited by this paper
• Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing Klebsiella Pneumoniae Bacteremia: A Case Report

  2019cited by this paper
• Successful treatment of septic shock due to NDM1-producing K. pneumoniae using ceftazidime-avibactam combined with aztreonam in solid organ transplant recipients: report of 2 cases.

  2019cited by this paper
• LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study

  2019cited by this paper
• Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae

  2019cited by this paper
• The role of fosfomycin for multidrug-resistant gram-negative infections.

  2019cited by this paper
• The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections

  2019cited by this paper
• Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

  2019cited by this paper
• Genomics for Molecular Epidemiology and Detecting Transmission of Carbapenemase-Producing Enterobacterales in Victoria, Australia, 2012 to 2016

  2019cited by this paper
• The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

  2019cited by this paper
• Outbreak of NDM-1-CTX-M-15-DHA-1 producing Klebsiella pneumoniae high-risk clone in Spain due to an undetectable colonized patient from Pakistan.

  2019cited by this paper
• In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae

  2018cited by this paper
• Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

  2018cited by this paper
• Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK)

  2018cited by this paper
• Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.

  2018cited by this paper
• Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection

  2018cited by this paper
• The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters.

  2018cited by this paper
• Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.

  2018cited by this paper
• Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review

  2018cited by this paper
• Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae

  2018cited by this paper
• Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors

  2018cited by this paper
• Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents

  2018cited by this paper
• Mobile Genetic Elements Associated with Antimicrobial Resistance

  2018cited by this paper
• In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

  2018cited by this paper
• Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria

  2018cited by this paper
• Successful Treatment of Bacteremia Due to NDM-1-Producing Morganella morganii with Aztreonam and Ceftazidime-Avibactam Combination in a Pediatric Patient with Hematologic Malignancy

  2018cited by this paper
• Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

  2018cited by this paper
• Prevalence of metallo-β-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan

  2018cited by this paper
• Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae

  2018cited by this paper
• Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.

  2017cited by this paper
• WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “β-Lactam Enhancer” Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones

  2017cited by this paper
• 1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients

  2017cited by this paper
• Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections in a Chinese Children's Hospital: Predominance of New Delhi Metallo-β-Lactamase-1

  2017cited by this paper
• In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

  2017cited by this paper
• Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae

  2017cited by this paper
• In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria

  2017cited by this paper
• Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

  2017cited by this paper
• Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa

  2017cited by this paper
• Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network

  2017cited by this paper
• In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

  2017cited by this paper
• Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

  2017cited by this paper
• Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

  2017cited by this paper
• WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &bgr;-lactamases

  2017cited by this paper
• Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China

  2017cited by this paper
• Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam

  2017cited by this paper
• Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases.

  2016cited by this paper
• In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

  2016cited by this paper
• B1-Metallo-β-Lactamases: Where Do We Stand?

  2016cited by this paper
• Epidemiology of infections caused by polymyxin-resistant pathogens.

  2016cited by this paper
• In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

  2015cited by this paper
• Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

  2015cited by this paper
• Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial

  2015cited by this paper
• Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015.

  2015cited by this paper
• The increasing threat of Pseudomonas aeruginosa high-risk clones.

  2015cited by this paper
• Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa

  2015cited by this paper
• Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?

  2015cited by this paper
• Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes.

  2014cited by this paper
• Antibiotic Resistance Pattern and Evaluation of Metallo-Beta Lactamase Genes Including bla-IMP and bla-VIM Types in Pseudomonas aeruginosa Isolated from Patients in Tehran Hospitals

  2014cited by this paper
• The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide.

  2014cited by this paper
• Metallo‐β‐lactamase structure and function

  2013cited by this paper
• Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin

  2012cited by this paper

• Emergence of A Novel Transferable Megaplasmid Driving blaVIM-24 and tmexCD3-toprJ3 Dissemination in Clinical Pseudomonas fulva Isolates.

  2025cites this paper
• New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria

  2024cites this paper
• Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study

  2024cites this paper
• Novel resistance ICEs carrying the blaFIM-1 metallo-β-lactamase gene from an ST235 Pseudomonas aeruginosa sublineage

  2024cites this paper
• Green synthesis of N,S dual heteroatom-doped fluorescent carbon dots (N,S-CDs) and their applications in gentamicin sensing and dual-switch anti-counterfeiting encryption

  2024cites this paper
• Interpreting the results of rapid molecular diagnostic tests for carbapenem-resistant Enterobacterales infection: current clinical perspective while waiting for further evidence

  2024cites this paper
• Impact of Persistent Multidrug-Resistant Gram-Negative Bacteremia on Clinical Outcome and Mortality

  2023cites this paper
• Treatment options for infections caused by multidrug-resistant Gram-negative bacteria: a guide to good clinical practice.

  2023cites this paper
• Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill: A Narrative Review

  2023cites this paper
• Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.

  2023cites this paper
• In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.

  2022cites this paper
• Innovative β-lactam/β-lactamase inhibitor combinations for carbapenem-resistant Gram-negative bacteria.

  2022cites this paper
• In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria

  2022cites this paper
• Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long?

  2022cites this paper
• Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022

  2022cites this paper
• Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies

  2021cites this paper
• Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections

  2021cites this paper
• Management of Infections caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions.

  2021cites this paper
• Role of new antibiotics in extended-spectrum β-lactamase-, AmpC- infections

  2021cites this paper
• New antibiotics for the treatment of nonfermenting Gram-negative bacteria

  2021cites this paper
• The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

  2021cites this paper
• Polymyxin Resistance in Enterobacterales: Overview and Epidemiology in the Americas.

  2021cites this paper